Monopar Therapeutics MNPR Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Monopar Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's debt-to-equity?
- Monopar Therapeutics (MNPR) reported debt-to-equity of 0× in Q1 2026.
- How has Monopar Therapeutics's debt-to-equity changed year-over-year?
- Monopar Therapeutics's debt-to-equity increased by 750.0% year-over-year, from 0× to 0×.
- What is the long-term trend for Monopar Therapeutics's debt-to-equity?
- Over 2 years (2022 to 2025), Monopar Therapeutics's debt-to-equity has grown at a -43.3% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.